Tony Coles, Cerevel CEO
Cerevel's stock rockets up on release of early data in schizophrenia, followed by an offering
A couple of years ago, when Pfizer shut down its neuroscience division, Bain Capital picked up the pieces and spun them out into a new …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
